Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Feb 1;19(2):281-288.
doi: 10.1093/neuonc/now149.

Dynamic O-(2-18F-fluoroethyl)-L-tyrosine positron emission tomography differentiates brain metastasis recurrence from radiation injury after radiotherapy

Affiliations

Dynamic O-(2-18F-fluoroethyl)-L-tyrosine positron emission tomography differentiates brain metastasis recurrence from radiation injury after radiotherapy

Garry Ceccon et al. Neuro Oncol. .

Abstract

Background: The aim of this study was to investigate the potential of dynamic O-(2-[18F]fluoroethyl)-L-tyrosine (18F-FET) PET for differentiating local recurrent brain metastasis from radiation injury after radiotherapy since contrast-enhanced MRI often remains inconclusive.

Methods: Sixty-two patients (mean age, 55 ± 11 y) with single or multiple contrast-enhancing brain lesions (n = 76) on MRI after radiotherapy of brain metastases (predominantly stereotactic radiosurgery) were investigated with dynamic 18F-FET PET. Maximum and mean tumor-to-brain ratios (TBRmax, TBRmean) of 18F-FET uptake were determined (20-40 min postinjection) as well as tracer uptake kinetics (ie, time-to-peak and slope of time-activity curves). Diagnoses were confirmed histologically (34%; 26 lesions in 25 patients) or by clinical follow-up (66%; 50 lesions in 37 patients). Diagnostic accuracies of PET parameters for the correct identification of recurrent brain metastasis were evaluated by receiver-operating-characteristic analyses or the chi-square test.

Results: TBRs were significantly higher in recurrent metastases (n = 36) than in radiation injuries (n = 40) (TBRmax 3.3 ± 1.0 vs 2.2 ± 0.4, P < .001; TBRmean 2.2 ± 0.4 vs 1.7 ± 0.3, P < .001). The highest accuracy (88%) for diagnosing local recurrent metastasis could be obtained with TBRs in combination with the slope of time-activity curves (P < .001).

Conclusions: The results of this study confirm previous preliminary observations that the combined evaluation of the TBRs of 18F-FET uptake and the slope of time-activity curves can differentiate local brain metastasis recurrence from radiation-induced changes with high accuracy. 18F-FET PET may thus contribute significantly to the management of patients with brain metastases.

Keywords: FET PET; kinetic analysis; radiation-induced changes; radionecrosis; stereotactic radiosurgery.

PubMed Disclaimer

Figures

Fig. 1.
Fig. 1.
58-year old patient (#4) with a brain metastasis of a non–small cell lung cancer. Twenty-nine months after stereotactic radiosurgery (SRS), MRI suggests tumor recurrence. In line with MRI findings, 18F-FET PET shows increased metabolic activity (TBRmean = 2.2), and the slope of the late phase of the TAC (20–50 min postinjection) is −0.72 SUV/h. Histology after resection was consistent with a recurrent brain metastasis (hematoxylin and eosin stain; original magnification ×400; scale bar, 1000 µm).
Fig. 2.
Fig. 2.
61-year old patient (#52) with a brain metastasis of a non–small cell lung cancer. Nine months after stereotactic radiosurgery (SRS), MRI suggests tumor recurrence. In contrast, 18F-FET PET shows no increased metabolic activity (TBRmean = 1.6), and the slope of the TAC is 0.38 SUV/h. Histology after stereotactic biopsy revealed fibrohyaline-thickened blood vessel walls and amorphic tissue necroses with rims of macrophages. The findings are compatible with actinic angiopathy and radiation necrosis (hematoxylin and eosin stain; original magnification ×100; scale bar, 1000 µm).

References

    1. Suh JH. Stereotactic radiosurgery for the management of brain metastases. N Eng J Med. 2010;362(12):1119–1127. - PubMed
    1. Andrews DW, Scott CB, Sperduto PW et al. . Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet. 2004;363(9422):1665–1672. - PubMed
    1. Aoyama H, Shirato H, Tago M et al. . Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial. JAMA. 2006;295(21):2483–2491. - PubMed
    1. Kocher M, Soffietti R, Abacioglu U et al. . Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study. J Clin Oncol. 2011;29(2):134–141. - PMC - PubMed
    1. Stockham AL, Tievsky AL, Koyfman SA et al. . Conventional MRI does not reliably distinguish radiation necrosis from tumor recurrence after stereotactic radiosurgery. J Neurooncol. 2012;109(1):149–158. - PubMed

MeSH terms